WuXi Biologics and WuXi XDC Congratulate DualityBio on Entering Global Licensing and Collaboration Agreements with BioNTech to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics

WuXi Biologics congratulated partner DualityBio on their exclusive licensing agreements with BioNTech for two antibody-drug conjugate (ADC) therapeutics focused on cancer and autoimmune diseases.

Rhea-AI Summary

WuXi Biologics congratulated partner DualityBio on their exclusive licensing agreements with BioNTech for two antibody-drug conjugate (ADC) therapeutics focused on cancer and autoimmune diseases.

WuXi Bio provided technical services to support the development of these products through its integrated service platforms. WuXi's advanced technology platforms have helped clients secure partnerships and drive global collaborations in the biotech sector.

With over 12,000 employees across multiple countries, WuXi Biologics is committed to supporting diverse projects and advancing bioconjugate therapies. As of December 31, 2022, WuXi is managing 588 integrated client projects, including 17 in commercial manufacturing, showcasing its strong market position in the biologics sector.

Positive

• WuXi Biologics supported DualityBio in securing licensing agreements with BioNTech for two ADC therapeutics.
• The partnership highlights WuXi's expertise and integrated service platforms in the biotech domain.
• WuXi is handling 588 integrated client projects and has 17 in commercial manufacturing as of December 31, 2022.

Negative

• None.

Argus Session date unavailable

-0.91% session move Open Argus

Details

News Market Reaction – WXXWY

The recorded move for WXXWY in the trading session of this news was -0.91%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SHANGHAI, April 17, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) and its subsidiary WuXi XDC congratulate their partner DualityBio, a clinical-stage biotech company focusing on the discovery and development of next generation ADC therapeutics for patients with cancer and autoimmune diseases, on entering into exclusive license and collaboration agreements with German based BioNTech, a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, for two investigative antibody-drug conjugates ("ADC") therapeutics.

WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.

"We congratulate DualityBio for the license agreements for two of their ADC candidates and are pleased to have been able to support DualityBio with our diverse services and expertise in the field of ADC products," commented Dr. Chris Chen, CEO of WuXi Biologics, "Over the last couple of years, our advanced technology platforms and high-quality services have supported our clients to win the trust of their partners, which facilitates multiple global collaborations between biotech and multinational pharmaceutical companies."

"Congratulations to DualityBio on reaching the license agreements with BioNTech. We are honored to support innovative partners such as DualityBio in advancing ADCs with our premier quality systems and extensive expertise," commented Dr. Jimmy Li, CEO of WuXi XDC, "Innovative and differentiated ADCs are emerging driven by unmet medical needs. As a global CRDMO dedicated to bioconjugates, we'll continue to accelerate and transform the discovery, development and manufacturing of bioconjugates, supporting our global partners for the benefit of patients globally."

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2022, WuXi Biologics is supporting 588 integrated client projects, including 17 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

About WuXi XDC

WuXi XDC, a joint venture between WuXi Biologics and WuXi STA, provides end-to-end contract research, development and manufacturing services for bioconjugates, including antibody drug conjugates (ADCs). The company's services cover antibodies and other biologics, chemical payloads and linkers, as well as bioconjugated drug substance and drug product. WuXi XDC has been successful in bringing multiple ADC projects to the Investigational New Drug (IND) filing stage in 15 months or less, nearly cutting in half the traditional development timeline. As of December 31, 2022, 393 projects – from early stage to late-stage clinical – are being developed at WuXi XDC, including 40 IND-completed projects and 10 projects in phase II/III. For more information about WuXi XDC, please visit: https://www.wuxibiologics.com/services-solutions/#XDC.

View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-and-wuxi-xdc-congratulate-dualitybio-on-entering-global-licensing-and-collaboration-agreements-with-biontech-to-accelerate-development-of-differentiated-antibody-drug-conjugate-therapeutics-301798575.html

SOURCE WuXi XDC

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the significance of WuXi Biologics' support for DualityBio's agreements with BioNTech?

WuXi Biologics' support underscores its role in facilitating important partnerships in the biotech industry, particularly in advancing ADC therapeutics.

How many projects is WuXi Biologics currently managing?

WuXi Biologics is managing a total of 588 integrated client projects as of December 31, 2022.

What type of therapeutics are involved in the agreements announced on April 17, 2023?

The agreements involve two investigational antibody-drug conjugate (ADC) therapeutics aimed at treating cancer and autoimmune diseases.

When were the licensing agreements between DualityBio and BioNTech announced?

The licensing agreements were announced on April 17, 2023.

What does the CRDMO sector stand for in relation to WuXi Biologics?

CRDMO stands for Contract Research, Development, and Manufacturing Organization, which describes WuXi Biologics' business model.